Teloduo Tablet 80/20 mg
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
MFDS item code 201907253 · Approved 2019.10.15
This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension; improvement of dyslipidemia; reduction of cardiovascular risk and inhibition of atherosclerosis progression
This medicine is used for patients who need to take telmisartan and rosuvastatin together. Telmisartan helps to treat essential hypertension and reduce the risk of myocardial infarction, stroke, and death from cardiovascular disease in elderly patients at high cardiovascular risk. Rosuvastatin improves hypercholesterolemia and familial hypercholesterolemia that are difficult to control with diet and exercise, delays the progression of atherosclerosis, and reduces the risk of cardiovascular diseases. It is also effective in reducing the risk of stroke, myocardial infarction, and vascular reconstruction. The combined use of these two medications is employed to comprehensively manage cardiovascular health.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, so it should be stopped immediately if pregnancy is confirmed. Those allergic to this medication or its components, pregnant or potentially pregnant women, and nursing individuals should not take this medication. Patients with severely impaired liver or kidney function, certain liver diseases, muscle disorders, and those taking certain medications must consult with a doctor before using this medication. Elderly patients or those with high blood potassium levels and slightly impaired liver function should use this medication cautiously and undergo regular liver function tests as needed. This medication can cause muscle pain, weakness, and rarely, severe muscle damage; therefore, if unexplained muscle pain or weakness occurs during treatment, the doctor should be informed immediately. This medication lowers blood pressure, so caution is needed as symptoms of hypotension (such as dizziness and fainting) may occur. Liver function abnormalities may arise, so if liver function test results exceed normal ranges, consultation with a physician is necessary. This medication may interact with other drugs, so if there are any concomitant medications, it is essential to inform healthcare providers. Pregnant or nursing women should not take this medication, and those planning to become pregnant should use appropriate contraceptive methods. The safety and efficacy in children have not been established, so it is not recommended. Overdose may present with symptoms such as hypotension, dizziness, and worsening kidney function, so immediate medical attention is required if these symptoms occur. During treatment, caution is advised while driving or operating hazardous machinery due to potential drowsiness or dizziness.
Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, decreased sensation, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, headache, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, arthralgia, fatigue, numbness, chest discomfort, syncope, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius.
White oval film-coated tablet
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.